Tagraxofusp, a CD123-directed cytotoxin that fuses recombinant human interleukin-3 with truncated diphtheria toxin, has shown clinical benefits in adult patients with untreated or relapsed BPDCN [2]. Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.